Maxwell Samuda, a former contestant on ITV’s Love Island, has made headlines as he opens up about health issues he believes are connected to a controversial pregnancy drug, diethylstilbestrol (DES), taken by his grandmother in the 1970s. This revelation has ignited calls for a public inquiry into the drug’s long-term effects, which have reportedly impacted multiple generations of his family.
A Troubling Legacy
Diethylstilbestrol, a synthetic form of the hormone oestrogen, was prescribed to approximately 300,000 women between the 1940s and 1970s. Initially touted as a means to prevent miscarriages and manage various pregnancy-related conditions, it has since been linked to a range of severe health issues, including infertility and various cancers. Samuda’s family, particularly his mother Natalie and grandmother Maureen, have faced significant health challenges they attribute to this drug.
Maureen Day, aged 78, believes she ingested DES during her second pregnancy in the early 1970s to avert miscarriage after suffering a previous loss. Four years ago, she was diagnosed with breast cancer. Her daughter, Natalie Samuda, 50, has also endured serious health complications, including pre-cancerous cells and a full hysterectomy, alongside multiple autoimmune disorders.
The Personal Toll
At just 26, Maxwell Samuda has already had to navigate his own health challenges, including surgery for undescended testes as an infant and a recent diagnosis of low sperm count. He has openly expressed his concerns about the implications of these issues on his future family plans. “Being told that you might potentially have issues with having a family—something I’ve always taken for granted—was unsettling,” he shared. “It’s frustrating to know that it stems from something I had no control over, decades ago.”
The family’s experiences have prompted them to advocate for a comprehensive inquiry into the drug’s effects and a compensation scheme for those affected. They have joined forces with the campaign group DES Justice UK (DJUK), which is pushing for recognition of the drug’s harmful legacy.
A Call for Action
The call for a public inquiry has garnered attention, with DJUK highlighting that DES was linked to serious health risks, including clear cell adenocarcinoma, a rare form of cancer affecting the cervix and vagina, as early as 1971. Despite this, the drug continued to be prescribed in Europe until the late 1970s, leaving many families grappling with the consequences.
Maxwell’s mother, Natalie, who has a background in midwifery, emphasised the need for accountability: “It’s crucial to understand how and why this happened to ensure it does not occur again. Many lives have been severely affected.” She also noted that her older sister, who did not take DES, has faced no health issues, raising questions about the drug’s selective impact.
The Ongoing Impact of DES
The narrative surrounding DES is a poignant reminder of the trust placed in medical professionals and the systemic failures that can arise. DJUK, which now has over 500 members, recently met with Health Secretary Wes Streeting to advocate for a public inquiry, describing the situation as a “silent scandal.” They are also calling for an NHS screening programme to identify individuals who may be at risk due to their exposure to DES.
Clare Fletcher, a partner at the law firm representing DJUK, expressed the urgency of addressing this issue: “The stories of Maureen, Natalie, and Maxwell reflect a broader tragedy affecting countless families. This is not just a historical injustice; it continues to impact lives today.”
While compensation schemes have been established for DES victims in the United States and the Netherlands, the UK has yet to create a similar provision, leaving many families without recourse.
Why it Matters
The plight of Maxwell Samuda and his family underscores the importance of transparency and accountability in healthcare. As they advocate for justice and recognition of the suffering caused by DES, their story highlights the need for rigorous investigation and support for those affected by past medical practices. The legacy of DES serves as a cautionary tale, reminding us of the imperative to prioritise patient safety and the ethical responsibility of medical practitioners to protect future generations.
